England’s National Institute for Health and Care Excellence (NICE) has given a second thumbs down to a pair of Alzheimer’s ...

Lecanemab and donanemab were hailed as 'the beginning of the end' of dementia last year, after studies showed they both slowed the progression of the memory-robbing illness.

Lecanemab and donanemab were hailed as 'the beginning of the end' of dementia last year, after studies showed they both ...

The legislation would require voters to approve the $3 billion start-up cost, and then the fund would be maintained at no ...

Bhattacharya became a plaintiff in a Supreme Court case, Murthy v. Missouri, arguing he was “unfairly censored” on social ...

The Media Online’s weekly round up of people, account and business moves in media. This week’s BIG move: WPP announces ...

The company confirmed this morning that NICE has taken the "unusual decision" to hold a third appraisal committee meeting as ...

President Trump's nominee to lead the National Institutes of Health promises to bring transparency to taxpayer-funded ...

Presented by The Coalition to Strengthen America’s Healthcare — Senators on Wednesday pressed Trump’s pick to head the ...

Additional evidence has prompted NICE to launch a second consultation on its decision not to recommend new Alzheimer’s ...

The most telling signal from Jay Bhattacharya’s confirmation hearing as nominee to direct the NIH lay in what he would not ...

Stanford University health policy professor and economist Jay Bhattacharya is poised to become the next director of the National Institutes of Health (NIH) after testifying before a key US Senate ...